Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial fo...
Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 88 27 91 00
Fax: 33 3 88 27 91 11
Address:
400, boulevard Gonthier d’Andernach, Parc d’innovation CS80166 Cedex, Illkirch-Graffenstaden, France
